It appears to the Securities and Exchange Commission (the “Commission”) that the public interest and the protection of investors require a suspension in the trading of the securities of Moleculin Biotech, Inc. (“Moleculin” or “the Company”) (CIK No. 0001659617) because of questions regarding the accuracy and adequacy of information in the marketplace about the Company and its securities. Those questions relate to, among other things, statements made by Moleculin and others, in its Form 10-K filed with the Commission on March 19, in press releases on March 20 and April 8, and in other statements on March 19, March 20, and April 16 concerning the company’s business, including the status of development of a drug candidate labeled WP1122 for potential application to COVID-19, and the Company’s ability to expedite regulatory approval of any such treatment.

Moleculin is a Delaware corporation with its principal office in Houston, Texas. The Company’s common stock is listed on the NASDQ stock exchange under the symbol MBRX. As of April 21, 2020, Moleculin’s common stock had 27 market makers.

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed Company.
THEREFORE, IT IS ORDERED, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in the securities of the above-listed Company is suspended for the period from 9:30 a.m. EDT on May 4, 2020, through 11:59 p.m. EDT on May 15, 2020.

By the Commission.

Vanessa A. Countryman
Secretary